These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 36193561)

  • 1. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.
    Yang J; Luly KM; Green JJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Mar; 15(2):e1853. PubMed ID: 36193561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobiotechnology-based drug delivery to the central nervous system.
    Jain KK
    Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Nanoparticle Approaches in Nose to Brain Drug Delivery and Anticancer Therapy - A Review.
    Ansari MA; Chung IM; Rajakumar G; Alzohairy MA; Alomary MN; Thiruvengadam M; Pottoo FH; Ahmad N
    Curr Pharm Des; 2020; 26(11):1128-1137. PubMed ID: 31951165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery.
    Mollé LM; Smyth CH; Yuen D; Johnston APR
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1809. PubMed ID: 36416028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.
    Stanimirovic DB; Sandhu JK; Costain WJ
    BioDrugs; 2018 Dec; 32(6):547-559. PubMed ID: 30306341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies.
    Padmakumar S; D'Souza A; Parayath NN; Bleier BS; Amiji MM
    J Control Release; 2022 Dec; 352():121-145. PubMed ID: 36252748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in nonviral vectors for gene delivery.
    Guo X; Huang L
    Acc Chem Res; 2012 Jul; 45(7):971-9. PubMed ID: 21870813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonviral approaches for neuronal delivery of nucleic acids.
    Bergen JM; Park IK; Horner PJ; Pun SH
    Pharm Res; 2008 May; 25(5):983-98. PubMed ID: 17932730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Customizing delivery nano-vehicles for precise brain tumor therapy.
    Miao YB; Zhao W; Renchi G; Gong Y; Shi Y
    J Nanobiotechnology; 2023 Jan; 21(1):32. PubMed ID: 36707835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances.
    Ekhator C; Qureshi MQ; Zuberi AW; Hussain M; Sangroula N; Yerra S; Devi M; Naseem MA; Bellegarde SB; Pendyala PR
    Cureus; 2023 Aug; 15(8):e44302. PubMed ID: 37649926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery.
    Maher R; Moreno-Borrallo A; Jindal D; Mai BT; Ruiz-Hernandez E; Harkin A
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
    Zhou X; Smith QR; Liu X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive nanoparticle strategies for brain tumor targeting.
    Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
    Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.